Paper Review Records
All Paper Review Records
15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Morpholino-mediated splice switching of NELFE suppresses hepatocellular carcinoma cell phenotypes in vitro and in vivo
Laura M. Reynolds; Ryan Lamm; Kai Zhang; Anna E. Barry-Wolbers; Alvaro Lucci; Brittany N. Ruiz; Corinne E. Wessner; Trish Nguyen; Kayla M. Hammond; Christoph Eckert; Ji-Bin Liu; Pongsakorn Choochuen; Kai Ying Hong; Wei Jiang; Marshonna Forgues; Gaia M. Palazzo; Daniel Lin; Adam S. Bodzin; Ashesh P. Shah; Xin Wei Wang; Sean P. Martin; Nicolas L. Fawzi; Matthias M. Gaida; John R. Eisenbrey; Hien DangShow moreShow less
Department of Surgery, Thomas Jefferson University, Philadelphia, PA 19107, USA; Department of Radiology, Thomas Jefferson University, Philadelphia, PA 19107, USA; Department of Pathology and Genome Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA; Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA; Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA; Institute of Pathology, University Medical Center Mainz, JGU-Mainz, 55131 Mainz, Germany; TRON, Translational Oncology at the University Medical Center, JGU-Mainz, 55131 Mainz, Germany; Laboratory of Human Carcinogenesis, National Cancer Institute, Bethesda, MD 20892, USA; Liver Cancer Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA; Department of Surgery, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA; Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, RI 02912, USAShow moreShow less
Systemic and local delivery of siRNA to the CNS and periphery via anti-IGF1R antibody conjugation
Mengnan Tian; Mehran Nikan; Miran Yoo; Stephanie Klein; Seung-Hwan Kwon; John Matson; Dongin Kim; Jinwon Jung; Sumin Hyeon; Byeong Min Yoo; Hyeon Ji Park; Michael Tanowitz; Asa Wahlander; Weon-Kyoo You; Hakju Kwon; Janel Huffman; Thazha P. Prakash; Sang Hoon Lee; Hien Zhao; Sungwon AnShow moreShow less
Ionis Pharmaceuticals Inc., 2855 Gazelle Ct, Carlsbad, CA 92010, USA; ABL Bio Inc., 456, Bongeunsa-ro, Gangnam-gu, Seoul 06153, Republic of KoreaShow moreShow less
Segmented poly(A) tails with microRNA target sites confer tissue-specific regulation for mRNA therapeutics
Rui Qi; Hua Chen; Rui Chen; Hui Bao; Ying Sun; Ruiwen Xu; Lu Han; Yingmei Xu; Juan Li; Na Li; Qiang Li; Tingting Zhang; Kai Lv; Yijie Dong; Shan Cen; Weiguo ZhangShow moreShow less
RinuaGene Biotechnology Co., Ltd., Suzhou, Jiangsu, P.R. China; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaShow moreShow less
Integrated in vitro transcription and oligo-dT affinity chromatography enable multi-cycle reagent recycling for mRNA manufacturing
Adithya Nair; Jixin Qu; Manoj Pohare; Thomas C. Minshull; Caroline A. Evans; Klaudia M. Slowik; Kate A. Loveday; Zoe V.R. Ashcroft; Mabrouka Maamra; Helen E. Colley; Craig Murdoch; Mark J. Dickman; Zoltán KisShow moreShow less
School of Chemical, Materials and Biological Engineering, University of Sheffield, Mappin Street, Sheffield S1 3JD, UK; Department of Chemical Engineering, Imperial College London, South Kensington Campus, London SW7 2AZ, UK; School of Clinical Dentistry, University of Sheffield, 19 Claremont Crescent, Sheffield S10 2TA, UKShow moreShow less
Cas12a chRDNA-mediated in vivo genome editing for high specificity functional gene disruption
Marta Losa; Prachi Rajmane; Morena Stanaway; Mary Coons; Antonio Munoz; Vaibhavi Garish; Brandon Tan; Matt Thompson; Rachel Gonzalez; Glen Churchward; Arthur L.G. Owen; Jack Taylor; Zili An; Paul D. Donohoue; Scott Gradia; Meghdad Rahdar; Steven B. KannerShow moreShow less
Caribou Biosciences, Berkeley, CA 94710, USAShow moreShow less
Targeting liver angiotensinogen with siRNA enhances podocyte regeneration through renin lineage cells in experimental kidney disease
Loïs A.K. van der Pluijm; Angela Koudijs; A.H. Jan Danser; Joris I. Rotmans; Roel BijkerkShow moreShow less
Department of Internal Medicine (Nephrology) and the Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Centre, 2333ZA Leiden, the Netherlands; Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, 3015GD Rotterdam, the NetherlandsShow moreShow less
FAQ
How long does Molecular Therapy Nucleic Acids take to review a manuscript?
As of 2026-11-13, CrushSCI has 15 complete review records for Molecular Therapy Nucleic Acids. The fastest paper went from submission to acceptance in 103 days (Quantum molecular resonance and secretome synergistically unlocks a protective ceRNA axis in the human retinal pigment epithelium, received 2026-04-09, accepted 2026-07-21); the slowest took 297 days. The average is 196.8 days and the median is 200 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
